The risk of AIDS-defining events is decreasing over time in the German HIV-1 Seroconverter Cohort

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Altmann, Mathias ^a   an der Heiden, Matthias ^a   Scheufele, Ramona ^a   Hartmann, Katrin ^a   Houareau, Claudia ^a   Bartmeyer, Barbara ^a   Hamouda, Osamah ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

AIDS defining event; HAART effectiveness; HIV progression; Seroconverter

Indexed keywords

LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; ETHNIC GROUP; FEMALE; GERMAN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SEROCONVERSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; GERMANY; HIV-1; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84862203919     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-94     Document Type: Article

References (21)

1. Tarwater PM, Mellors J, Gore ME, Margolick JB, Phair J, Detels R, Munoz A. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol 2001, 154(7):675-681. 10.1093/aje/154.7.675, 11581102.
2. Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983, 2(2):267-271. 10.1002/sim.4780020222, 6648141.
3. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338(13):853-860. 10.1056/NEJM199803263381301, 9516219.
4. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998, 280(17):1497-1503. 10.1001/jama.280.17.1497, 9809730.
5. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000, 355(9210):1131-1137. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis.
6. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003, 362(9392):1267-1274.
7. Ewings FM, Bhaskaran K, McLean K, Hawkins D, Fisher M, Fidler S, Gilson R, Nock D, Brettle R, Johnson M, et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS 2008, 22(1):89-95. 10.1097/QAD.0b013e3282f3915e, 18090396.
8. Perez-Hoyos S, Ferreros I, del Amo J, Muga R, del Romero J, de Olalla PG, Hernandez-Aguado I. Survival and progression to AIDS in a seroconverter cohort in the post-highly active antiretroviral therapy era: effectiveness goes on. AIDS 2006, 20(2):289-291. 10.1097/01.aids.0000202651.41397.db, 16511426.
9. Kerwat K, Just M, Wulf H. The German Protection against Infection Act (Infektionsschutzgesetz (IfSG)). Anasthesiol Intensivmed Notfallmed Schmerzther 2009, 44(3):182-183. 10.1055/s-0029-1215548, 19266418.
10. Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, Somogyi S, Kollan C, Jessen H, Dupke S, Hamouda O. Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One 2010, 5(10):e12718. 10.1371/journal.pone.0012718, 2951346, 20949104.
11. Clayton CHM. Statistical models in epidemiology. 1993,
12. From the Centers for Disease Control and Prevention 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993, 269(6):729-730. From the Centers for Disease Control and Prevention.
13. Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, Somogyi S, Kollan C, Jessen H, Dupke S, Hamouda O, et al. Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One 2010, 5(10):e12718. 10.1371/journal.pone.0012718, 2951346, 20949104.
14. Williams IG, De Cock KM. The XI international conference on AIDS. Vancouver 712 July 1996. A review of Clinical Science Track B. Genitourin Med 1996, 72(5):365-369. 1195707, 8976856.
15. Robert Koch Institute Weekly report [Epidemiologisches Bulletin]. 2009, 48. Robert Koch Institute.
16. Antiretroviral therapy of HIV infection German-Austrian recommendations (July 2002). Eur J Med Res 2003, 8(6):257-274. Antiretroviral therapy of HIV infection.
17. Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008). Dtsch Med Wochenschr 2009, 134(Suppl 1):S4-15.
18. Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, Hernandez-Aguado I, Meyer L, Porter K, del Amo J. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol 2008, 168(5):532-540. 10.1093/aje/kwn179, 18663213.
19. van den Berg JB, Hak E, Vervoort SC, Hoepelman IM, Boucher CA, Schuurman R, Schneider MM. Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy. HIV Med 2005, 6(5):299-306. 10.1111/j.1468-1293.2005.00304.x, 16156876.
20. Lindback S, Brostrom C, Karlsson A, Gaines H. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 x 10(6)/l, AIDS, and death from AIDS?. BMJ 1994, 309(6968):1535-1537. 10.1136/bmj.309.6968.1535, 2541767, 7819891.
21. Tyrer F, Walker AS, Gillett J, Porter K. The relationship between HIV seroconversion illness, HIV test interval and time to AIDS in a seroconverter cohort. Epidemiol Infect 2003, 131(3):1117-1123. 10.1017/S0950268803001377, 2870061, 14959779.